English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/213006
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Impact of Sarcopenia and Frailty in a Multicenter Cohort of Polypathological Patients

AuthorsBernabeu Wittel, Máximo; González-Molina, Álvaro; Fernández-Ojeda, Rocío; Díez-Manglano, Jesús; Salgado, Fernando; Soto-Martín, María; Muniesa, Marta; Ollero Baturone, M.; Gómez-Salgado, Juan
KeywordsPolypathological patients
Multimorbidity
Sarcopenia
Frailty
Issue Date18-Apr-2019
PublisherMultidisciplinary Digital Publishing Institute
CitationJournal of Clinical Medicine 8(4): 535 (2019)
AbstractThe prevalence, relationships and outcomes of sarcopenia and frailty in polypathological patients remain unknown. We performed a multicenter prospective observational study in six hospitals in order to assess prevalence, clinical features, outcome and associated risk factors of sarcopenia and frailty in a hospital-based population of polypathological patients. The cohort was recruited by performing prevalence surveys every 14 days during the inclusion period (March 2012–June 2016). Sarcopenia was assessed by means of EWGSOP criteria and frailty by means of Fried’s criteria. Skeletal muscle mass was measured by tetrapolar bioimpedanciometry. All patients were followed for 12 months. Factors associated with sarcopenia, frailty and mortality were analyzed by multivariate logistic regression, and Kaplan–Meier curves. A total of 444 patients (77.3 ± 8.4 years, 55% males) were included. Sarcopenia was present in 97 patients (21.8%), this being moderate in 54 (12.2%), and severe in 43 (9.6%); frailty was present in 278 patients (62.6%), and 140 (31.6%) were pre-frail; combined sarcopenia and frailty were present in the same patient in 80 (18%) patients. Factors independently associated to the presence of both, sarcopenia and frailty were female gender, older age, different chronic conditions, poor functional status, low body mass index, asthenia and depressive disorders, and low leucocytes and lymphocytes count. Mortality in the 12-months follow-up period was 40%. Patients with sarcopenia, frailty or both survived significantly less than those without these conditions. Sarcopenia and frailty are frequent and interrelated conditions in polypathological patients, shadowing their survival. Their early recognition and management could improve health-related outcomes in this population.
DescriptionThis article belongs to the Section Endocrinology & Metabolism.
Publisher version (URL)https://doi.org/10.3390/jcm8040535
URIhttp://hdl.handle.net/10261/213006
DOIhttp://dx.doi.org/10.3390/jcm8040535
E-ISSN2077-0383
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
jcm-08-00535.pdf944,9 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.